Market Overview

UPDATE: JP Morgan Maintains Integra LifeSciences at Neutral Following Model Update

Share:
Related IART
Wall Street's M&A Chatter From September 11: Western Digital-Toshiba, Pilgrim's Pride-Moy Park, Gigamon And More
A Peek Into The Markets: U.S. Stock Futures Signal Higher Start On Wall Street

JP Morgan reiterated its Neutral rating and $43 price target on Integra LifeSciences (NASDAQ: IART).

JP Morgan commented, "For 2013, we continue to expect adjusted EPS of $3.14 (+1.3%) on total revenues of $878.1M (+5.5%). Excluding the impact of the medical device excise tax (~$0.29), earnings growth is projected at 10.7%. By division, we project Neuro growth of 4.0%, Orthopedics growth of 7.4%, and Instruments growth of (3.9%). Longer term, we see Integra as a 5-6% and 10-11% top- and bottom-line grower, respectively. This compares to management's long-term guidance ranges of 5-7% and 9-13%. For 2014, we model adjusted EPS of $3.48 (+11.2%) on total revenues of $925.6M (+5.4%)."

Integra LifeSciences closed at $38.78 on Wednesday.

Latest Ratings for IART

DateFirmActionFromTo
Jul 2017Raymond JamesMaintainsOutperform
Jul 2017Morgan StanleyMaintainsNeutral
Jun 2017Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for IART
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Related Articles (IART)

View Comments and Join the Discussion!
Loading...
Loading...